Εμφάνιση απλής εγγραφής

dc.creatorAlexiou A., Mantzavinos V.D., Greig N.H., Kamal M.A.en
dc.date.accessioned2023-01-31T07:30:51Z
dc.date.available2023-01-31T07:30:51Z
dc.date.issued2017
dc.identifier10.3389/fnagi.2017.00077
dc.identifier.issn16634365
dc.identifier.urihttp://hdl.handle.net/11615/70417
dc.description.abstractAlzheimer's disease treatment is still an open problem. The diversity of symptoms, the alterations in common pathophysiology, the existence of asymptomatic cases, the different types of sporadic and familial Alzheimer's and their relevance with other types of dementia and comorbidities, have already created a myth-fear against the leading disease of the twenty first century. Many failed latest clinical trials and novel medications have revealed the early diagnosis as the most critical treatment solution, even though scientists tested the amyloid hypothesis and few related drugs. Unfortunately, latest studies have indicated that the disease begins at the very young ages thus making it difficult to determine the right time of proper treatment. By taking into consideration all these multivariate aspects and unreliable factors against an appropriate treatment, we focused our research on a non-classic statistical evaluation of the most known and accepted Alzheimer's biomarkers. Therefore, in this paper, the code and few experimental results of a computational Bayesian tool have being reported, dedicated to the correlation and assessment of several Alzheimer's biomarkers to export a probabilistic medical prognostic process. This new statistical software is executable in the Bayesian software Winbugs, based on the latest Alzheimer's classification and the formulation of the known relative probabilities of the various biomarkers, correlated with Alzheimer's progression, through a set of discrete distributions. A user-friendly web page has been implemented for the supporting of medical doctors and researchers, to upload Alzheimer's tests and receive statistics on the occurrence of Alzheimer's disease development or presence, due to abnormal testing in one or more biomarkers. © 2017 Alexiou, Mantzavinos, Greig and Kamal.en
dc.language.isoenen
dc.sourceFrontiers in Aging Neuroscienceen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85017374924&doi=10.3389%2ffnagi.2017.00077&partnerID=40&md5=8e5b96e4ad59844caf6397803f7843fd
dc.subjectbiological markeren
dc.subjectadulten
dc.subjectageen
dc.subjectageden
dc.subjectAlzheimer diseaseen
dc.subjectArticleen
dc.subjectBayes theoremen
dc.subjectcontrolled studyen
dc.subjectdisease classificationen
dc.subjectearly diagnosisen
dc.subjecthumanen
dc.subjectMonte Carlo methoden
dc.subjectprognosisen
dc.subjectFrontiers Research Foundationen
dc.titleA Bayesian model for the prediction and early diagnosis of Alzheimer's diseaseen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής